Abstract
In 2010, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) started the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be (nuMoM2b), a prospective cohort study of a racially/ethnically/geographically diverse population of nulliparous women with singleton gestation. The nuMoM2b is a very large dataset, consisting of data for 10,038 patients with over 4,600 features per patient, spread out over 80 files. In this report, we share our experience preparing and working with this dataset. We present our data preprocessing of the nuMoM2b dataset to get a deeper understanding of the data, extract the most relevant features, make the fewest assumptions when filling in unknown values, and reducing the dimensionality of the data. We hope this report is useful to researchers interested in building machine learning and statistical models from the nuMoM2b dataset.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by NIH/NLM (www.nlm.nih.gov) grant R01LM013327
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human subjects approval for this study, titled "SCH: Prediction of Preterm Birth in Nulliparous Women", was obtained following review by Columbia University Human Subjects Institutional Review Board under number IRB-AAAR9413, and the City University of New York CUNY HRPP/IRB review number 2019-0855.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.